Coated Aldehyde Oxystarch for Protein-Bound Uremic Toxin Reduction in End-Stage Renal Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University People's Hospital

About this trial

The goal of this clinical trial is to learn if Coated Aldehyde Oxystarch (Xiqing) works to reduce protein-bound uremic toxins (PBUTs) in adults with end-stage renal disease (ESRD). It will also learn about the safety of Coated Aldehyde Oxystarch. The main questions it aims to answer are:

Does Coated Aldehyde Oxystarch lower the blood levels of protein-bound uremic toxins, such as indoxyl sulfate and p-cresyl sulfate?

What medical problems do participants have when taking Coated Aldehyde Oxystarch?

Researchers will compare the levels of PBUTs before treatment (baseline) with those after treatment with Coated Aldehyde Oxystarch to see if it works to reduce these toxins.

Participants will:

Take Coated Aldehyde Oxystarch (Xiqing) 10 capsules per time, three times daily (each capsule 0.625 g, total daily dose 18.75 g) for 3 months.

Visit the clinic every month for checkups and blood tests.

Provide blood samples to measure protein-bound uremic toxin levels and routine safety parameters.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years, no restriction on sex or ethnicity.

Receiving maintenance dialysis for at least 3 months, with dialysis regimen remaining unchanged during the trial period.

If taking other medications that do not interfere with gut microbiota prior to enrollment, they must have been stable for at least 1 month and the regimen must remain unchanged during the trial.

Ability to understand and voluntarily sign the informed consent form.

Disqualifiers

Known allergy to Coated Aldehyde Oxystarch.

History of or planned kidney transplantation within 6 months, or change in dialysis regimen.

Use of medications or supplements that may affect gut microbiota (e.g., antibiotics, probiotics, prebiotics, laxatives) within the past 3 months.

Diagnosis of serious gastrointestinal diseases, including gastrointestinal bleeding, colitis, inflammatory bowel disease, irritable bowel syndrome, history of intestinal obstruction, history of gastrectomy or duodenectomy.

Trial design

Design model

Single group

Treatments tested in this trial

  • Coated Aldehyde Oxystarch

    Drug

    Each capsule contains 0.625g of Coated Aldehyde Oxystarch. Participants will take 10 capsules per time, three times daily for 3 months.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: Experimental: Coated Aldehyde Oxystarch (Xiqing)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Absolute Change From Baseline in Serum Indoxyl Sulfate (IS) Level at Month 3

The absolute change in serum indoxyl sulfate (IS) level from baseline to Month 3 will be calculated as the serum IS level at Month 3 minus the serum IS level at baseline.

Time frame
Baseline, Month 3
2

Percentage Change From Baseline in Serum Indoxyl Sulfate (IS) Level at Month 3

The percentage change in serum indoxyl sulfate (IS) level from baseline to Month 3 will be calculated as: \[(serum IS level at Month 3 - serum IS level at baseline) / serum IS level at baseline\] × 100%.

Time frame
Baseline, Month 3

Secondary outcomes

1

Change in Serum Indoxyl Sulfate (IS) Level Over Time

Change from baseline in serum IS level at Month 1 and Month 2, in addition to Month 3. The trend of changes over different time points will be analyzed.

Time frame
Baseline, Month 1, Month 2, Month 3
2

Changes in Serum Phosphorus Levels

Change from baseline in serum phosphorus levels at Month 1, Month 2, and Month 3.

Time frame
Baseline, Month 1, Month 2, Month 3
3

Changes in Serum Calcium Levels

Change from baseline in serum calcium levels at Month 1, Month 2, and Month 3.

Time frame
Baseline, Month 1, Month 2, Month 3
4

Changes in Serum Potassium Levels

Change from baseline in serum potassium levels at Month 1, Month 2, and Month 3.

Time frame
Baseline, Month 1, Month 2, Month 3

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.